J 2019

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

CORSELLO, Tiziana, Amico GIANDOMENICO, Simona CORRAO, Rita ANZALONE, Francesca TIMONERI et. al.

Basic information

Original name

Wharton’s Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro

Authors

CORSELLO, Tiziana (380 Italy), Amico GIANDOMENICO (380 Italy), Simona CORRAO (380 Italy), Rita ANZALONE (380 Italy, guarantor), Francesca TIMONERI (380 Italy), Melania LO IACONO (380 Italy), Eleonora RUSSO (380 Italy), Giovanni Francesco SPATOLA (380 Italy), Maria Laura UZZO (380 Italy), Mario GIUFFRÈ (380 Italy), Martin CAPRNDA (703 Slovakia), Peter KUBATKA (703 Slovakia), Peter KRUŽLIAK (703 Slovakia, belonging to the institution), Pier Giulio CONALDI (380 Italy) and Giampiero LA ROCCA (380 Italy)

Edition

Stem Cell Reviews and Reports, SPRINGER, 2019, 2629-3269

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10601 Cell biology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.316

RIV identification code

RIV/00216224:14110/19:00113179

Organization unit

Faculty of Medicine

DOI

UT WoS

000511707800013

Keywords in English

Wharton’s jelly mesenchymal stromal cells; Immunomodulation; CD276; B7-H3; Lymphocyte inhibition; Stem cells; Human umbilical cord; Regenerative medicine; Cell therapy

Tags

Tags

International impact, Reviewed
Změněno: 12/3/2020 15:36, Mgr. Tereza Miškechová

Abstract

V originále

Therapeutic options for end-stage organ failure are often limited to whole organ transplantation. The tolerance or rejection of the transplanted organ is driven by both early non-specific innate and specific adaptive responses. The use of mesenchymal stromal cells (MSCs) is considered a promising tool in regenerative medicine. Human umbilical cord (HUC) is an easily available source of MSCs, without relevant ethical issues. Moreover, Wharton’s jelly-derived MSCs (WJ-MSCs), showed consistent immunomodulatory features that may be useful to promote immune tolerance in the host after transplantation. Few data are available on the phenotype of WJ-MSCs in situ. We investigated the expression of immune-related molecules, such as HLAs, IDO, CD276/B7-H3, and others, both in situ (HUC) and in in vitro-cultured WJ-MSCs. Morphological and biochemical techniques were used to define the expression of such molecules. In addition, we focused on the possible role of CD276/B7-H3 on T cells proliferation inhibition. We assessed CD276/B7-H3 expression by WJ-MSCs both in situ and alongside cell culture. WJ-MSCs were able to suppress T cell proliferation in mixed lymphocyte reaction (MLR). Moreover, we describe for the first time a specific role for CD276/B7-H3, since the immunomodulatory ability of WJ-MSCs was abolished upon anti-CD276/B7-H3 antibody addition to the MLR. These results further detail the immune regulation properties and tolerance induction exerted by human WJ-MSCs, in particular pointing to CD276/B7-H3 as one of the main involved factors. These data further suggest WJ-MSCs as potent tools to modulate local immune response in “support-type” regenerative medicine approaches.